Neumirna Therapeutics
PrivateLast Round
Series A
Jan 16, 2025
Total Funding Raised
$23.97M
Momentum Score
25 /100
Company Overview
Neumirna Therapeutics is a biotechnology company that develops miRNA-based therapies targeting the root causes of neurological diseases such as epilepsy and Parkinson's.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neumirna Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Neumirna Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 16, 2025 | ||||
| Grant | Jun 12, 2024 | ||||
| Grant | Feb 29, 2024 | ||||
| Grant | Dec 15, 2023 | ||||
| Grant | Aug 1, 2023 |
Neumirna Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovation Fund Denmark | Grant |
| Innovestor | Seed |
| CURE Epilepsy | Grant |
| Angelini Ventures | Series A |
| Innovestor Life Science Fund | Series A |
| Sunstone Life Science Ventures | Seed |
| Invivo Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 12, 2026
Presented RNA-based approach for drug-resistant epilepsy at AES Annual Meeting.
- Sep 17, 2025
Ellen K. Donnelly, Ph.D. appointed as new Chief Executive Officer.
Neumirna Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neumirna Therapeutics's valuation, stock price, and market status.
